(Q40399465)

English

Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients

scientific article published on 21 December 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients (English)

1 reference

Europe PubMed Central

20 September 2017

liver cirrhosis

0 references

Luis Enrique Morano Amado

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Antonio Rivero-Juarez

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Alberto Romero Palacios

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Juan Carlos Alados Arboledas

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

K Neukam

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

R Granados

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

M Márquez

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

D Merino

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

E Ortega

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

J Cucurull

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

M Omar

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

P Ryan-Murua

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Grupo de Estudio de Hepatitis Vírica, of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica: GEHEP-SEIMC and Grupo de Estudio de Hepatitis Vírica, of the Sociedad Andaluza de Enfermedades Infecciosas y Microbiología Clínica: HEPAVIR/Red de Investigación en SIDA (RIS-HEP07)

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

publication date

21 December 2016

1 reference

Europe PubMed Central

20 September 2017

European Journal of Clinical Microbiology & Infectious Diseases

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

36

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

853-861

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28004322%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

https://scigraph.springernature.com/pub.10.1007/s10096-016-2871-x

0 references

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Liver stiffness as a predictor of esophageal varices requiring therapy in HIV/hepatitis C virus-coinfected patients with cirrhosis.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Update on hepatitis C virus resistance to direct-acting antiviral agents

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

1 reference

https://api.crossref.org/works/10.1007%2FS10096-016-2871-X

21 January 2018

Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/28004322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/28004322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Index for rating diagnostic tests

1 reference

https://pubmed.ncbi.nlm.nih.gov/28004322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Dac

1 reference

https://pubmed.ncbi.nlm.nih.gov/28004322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40399465&oldid=1896925980"